Sophie V. Vandebroek - May 6, 2024 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Sophie V. Vandebroek
Stock symbol
IDXX
Transactions as of
May 6, 2024
Transactions value $
$0
Form type
4
Date filed
5/8/2024, 07:02 PM
Previous filing
May 2, 2024
Next filing
Nov 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $0 +257 +21.13% $0.00 1.47K May 6, 2024 Direct
holding IDXX Common Stock 8.17K May 6, 2024 By Sophie V. Vandebroek Revocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Award $0 +609 $0.00 609 May 6, 2024 Common Stock 609 $476.87 Direct F1
transaction IDXX Restricted Stock Unit Award $0 +262 $0.00 262 May 6, 2024 Common Stock 262 Direct F2
transaction IDXX Restricted Stock Unit Options Exercise $0 -257 -100% $0.00* 0 May 6, 2024 Common Stock 257 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.
F2 Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.
F3 Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event wa earlier.